News & Updates
Filter by Specialty:
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
23 Nov 2021Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?
The use of amphilimus-eluting stents (AES) in patients with diabetes mellitus undergoing percutaneous revascularization was less likely to result in target lesion or target vessel failure compared with zotarolimus-eluting stents (ZES) at 1 year, according to findings of the SUGAR trial presented at TCT 2021.
Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?
22 Nov 2021Finerenone lessens HF burden among patients with CKD, diabetes
Treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone helps prevent the incidence of new-onset heart failure (HF) and improve other HF outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as shown in a secondary analysis of the phase III FIGARO-DKD trial.
Finerenone lessens HF burden among patients with CKD, diabetes
22 Nov 2021Obesity ups risk of early-onset colorectal cancer
Obese people are more likely to develop early-onset colorectal cancer (CRC), suggests a study, noting that the increasing prevalence of obesity in younger generations may significantly contribute to the increase in this disease.
Obesity ups risk of early-onset colorectal cancer
22 Nov 2021Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
22 Nov 2021Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).